Experiment 1175631

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationANON:. (1986). INVESTIGATION OF THE ADDITIVE POTENTIAL OF TENIPOSIDE AND VINCRISTINE IN NON-HODGKIN'S LYMPHOMA.. 70(8)
Amount utilized
Compound isolated
DiseaseIN THIS COMPARATIVE STUDY OF DIFFERENT DRUG COMBINATIONS FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA, 64 PATIENTS WERE TREATED WITH A COMBINATION OF DOXORUBICIN, CYCLOPHOSPHAMIDE, TENIPOSIDE, AND PREDNISOLONE. 61% OF THE PATIENTS HAD STAGE IV ADVANCED DISEASE. 75% OF THE PATIENTS HAD RECEIVED NO PREVIOUS TREATMENT. PATIENTS WERE GIVEN AT LEAST 3 COURSES OF THERAPY, EACH COURSE WAS REPEATED AT 3 WEEK INTERVALS. 46% OF THE PATIENTS ACHIEVED COMPLETE REMISSION, AND RELAPSE FREE SURVIVAL OF OVER 5 YEARS WAS ESTIMATED AT 56%. GRADE 3 MYELOSUPPRESSION WAS SEEN IN 22% OF THE PATIENTS, AND GRADE 1 NEUROLOGIC TOXICITY IN 16% OF THE PATIENTS. THERE WERE NO CASES OF MORE SEVERE NEUROTOXICITY.
Dose amount50-99 MG
Number2
Qualitative resultEQUIVOCAL
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES